Opioid-galanin receptor heteromers mediate the dopaminergic effects of opioids

J Clin Invest. 2019 Mar 26;129(7):2730-2744. doi: 10.1172/JCI126912.

Abstract

Identifying non-addictive opioid medications is a high priority in medical sciences, but μ-opioid receptors mediate both the analgesic and addictive effects of opioids. We found a significant pharmacodynamic difference between morphine and methadone that is determined entirely by heteromerization of μ-opioid receptors with galanin Gal1 receptors, rendering a profound decrease in the potency of methadone. This was explained by methadone's weaker proficiency to activate the dopaminergic system as compared to morphine and predicted a dissociation of therapeutic versus euphoric effects of methadone, which was corroborated by a significantly lower incidence of self-report of "high" in methadone-maintained patients. These results suggest that μ-opioid-Gal1 receptor heteromers mediate the dopaminergic effects of opioids that may lead to a lower addictive liability of opioids with selective low potency for the μ-opioid-Gal1 receptor heteromer, exemplified by methadone.

Keywords: Addiction; G-protein coupled receptors; Neuroscience; Therapeutics.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Analgesics, Opioid / pharmacology*
  • Animals
  • Cell Line
  • Humans
  • Male
  • Methadone / pharmacology*
  • Morphine / pharmacology*
  • Protein Multimerization*
  • Rats
  • Rats, Sprague-Dawley
  • Receptor, Galanin, Type 1 / genetics
  • Receptor, Galanin, Type 1 / metabolism*
  • Receptors, Opioid, mu / genetics
  • Receptors, Opioid, mu / metabolism*

Substances

  • Analgesics, Opioid
  • Receptor, Galanin, Type 1
  • Receptors, Opioid, mu
  • Morphine
  • Methadone